HEALTH TECHNOLOGY

Northwell Health and Aegis Ventures Launch Ascertain – Healthcare AI Company Creation Platform to Improve Quality and Access to Care

Northwell Health | April 13, 2022

Northwell Health

Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a New York-based startup studio announced at their inaugural Healthcare AI Innovation Summit the finalization of definitive agreements to launch Ascertain, a joint company creation platform. Ascertain is a first-of-its-kind partnership that pairs a dynamic venture studio with one of the nation’s largest and most impactful health systems to develop and commercialize breakthrough healthcare AI companies that improve quality and access to care and close health equity gaps.

Ascertain represents a novel, more targeted approach to the way entrepreneurs and healthcare systems collaborate to solve major healthcare challenges. The platform combines clinical and business leadership, expert technical and product teams, access to Northwell’s leading, diverse datasets, and capital resources within a single ecosystem – with a sole focus on building and validating effective solutions that can be rapidly brought to market.

Ascertain brings a unique structure, an innovative approach, and a compelling vision to create breakthrough healthcare AI companies that are set up for success. We are all driven by the idea that everyone deserves access to high-quality, affordable healthcare. Our aim is clear: to find new, cost-efficient ways to create and accelerate companies that deliver real, equitable solutions.”

Michael Dowling, President and CEO of Northwell Health

Ascertain has commenced the creation of its first portfolio companies in partnership with Northwell’s clinicians and administrators. One such collaboration is focused on bringing substantive improvements in maternal health, working hand-in-hand with Northwell’s recently launched Center for Maternal Health to develop new approaches to detecting and managing serious complications for expectant mothers and babies. Ascertain’s data science team has been working hand-in-hand with Northwell’s Maternal and Fetal Medicine team to examine tens of thousands of cases of preeclampsia, a hypertensive pregnancy complication that disproportionately affects Black mothers in the United States.

Using cutting-edge data science techniques, the Ascertain team aims to deliver an AI solution that helps clinicians predict the risk of developing preeclampsia, enabling them to intervene earlier than previously possible.

“Existing approaches to the detection of preeclampsia often occur too late in pregnancy, once the condition has begun to manifest. An important enabler for a solution to this challenge is predictive analytics, applying available knowledge of a patient's history to enable action far earlier with simple, yet life-saving, clinical interventions. We believe the AI solution Ascertain is currently developing will enable this,” shared Burt Rochelson, MD, Chief of Maternal Medicine at Northwell Health.

“Aegis and Northwell’s multidisciplinary teams are pursuing innovation through a systematic approach that will bring validated solutions to patients more quickly and at a lower cost,” said Bill Schoenfeld, Aegis Ventures Chairman. “Our skillsets are extraordinarily complementary and enable us to address healthcare’s most entrenched quality, equity, and cost problems far more powerfully than either organization could alone.”

Ascertain is preparing to launch multiple companies in 2022 that focus on maternal health, chronic disease detection and management, and next-generation AI tools.

Ascertain’s Chairman Tom Manning shared, “Together, we’re paving a new way forward, a monumental step toward real, proven AI solutions that can bring impact to the world. It is a bold collaboration to drive AI-backed companies that save lives and resolve long-standing health inequities – and realize results that deliver something greater in healthcare.”

Ascertain is committed to building exceptional teams that will embrace this unique opportunity to create unparalleled impact. To learn more about Ascertain or register your interest, please visit https://ascertain.com/.

About Ascertain
Ascertain is a revolutionary new partnership between Northwell Health, New York’s largest healthcare provider, and Aegis Ventures, a dynamic startup studio. This unique partnership assembles leading medical, technology, and business resources to create a first-of-its-kind company creation platform for healthcare innovation to address healthcare’s most challenging quality, equity, and cost problems. Ascertain brings $100M in seed-stage capital to bear in pursuit of a three-pronged approach to company creation: internal ideation, commercialization of scientific breakthroughs, and US market entry partnerships for global ventures. Ascertain creates companies that improve quality of care, patient experience, and long-standing health, placing patient needs at the center of every business model, technology solution, and product.

About Northwell Health
Northwell Health is New York State’s largest healthcare provider and private employer, with 23 hospitals, 830 outpatient facilities and more than 16,600 affiliated physicians. We care for over two million people annually in the New York metro area and beyond, thanks to philanthropic support from our communities. Our 77,000 employees – 18,900 nurses and 4,800 employed doctors, including members of Northwell Health Physician Partners – are working to change healthcare for the better. We’re making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies.

About Aegis Ventures
Aegis Ventures is a next-generation startup studio that partners with entrepreneurs and industry leaders to originate, launch, and scale transformative companies. Our platform brings together market-shaping ideas, permanent growth capital, and ambitious individuals driven to solve major societal problems. We aim to build companies with the capacity for vast impact, with an initial focus on artificial intelligence and digital health. Within these verticals, Aegis seeks to create companies that leverage technology to better optimize tradeoffs between quality, access, and cost, focusing on innovations that promote seamless continuity of care, patient empowerment, and better-informed clinical decision-making.

Spotlight

THE CANADIAN DIABETES RISK QUESTIONNAIRE (developed by the Public Health Agency of Canada) helps identify individuals that are at higher risk of having pre-diabetes or type 2 diabetes. The questionnaire is intended for adults aged 40 to 74 years. Pre-diabetes is a condition where a person‘s blood sugar levels are higher than normal, but not high enough to be diagnosed as diabetes. You can have pre-diabetes or undiagnosed type 2 diabetes without having any obvious warning signs or symptoms.


Other News
HEALTH TECHNOLOGY

KAID Health Technology Demonstrates the Value of Natural Language Processing to Improve Preoperative Care

KAID Health | August 02, 2022

KAID Health, an AI-powered health care data analysis and provider engagement platform, announced the results of a study that validates the potential utility of its Natural Language Processing technology to improve provider efficiency and care quality. The peer-reviewed “doctor vs. artificial intelligence” paper found that KAID Health’s NLP technology greatly aligned with the clinician reviewers in completing a pre-operative checklist, and further was able to identify 16.6% of instances where the presence or absence of a specific condition was not found by the anesthesiologist. The research study was undertaken at UCSD’s Department of Anesthesiology, Division of Perioperative Informatics. The authors of the manuscript were Harrison S. Suh, BS, Jeffrey L. Tully, MD, Minhthy N. Meineke, MD, Ruth S. Waterman, MD, MS, and Rodney A. Gabriel, MD, MAS. “We have demonstrated that NLP technology can help identify critical medical conditions relevant to preanesthetic evaluation. Key to this was KAID Health’s ability to utilize unstructured free-text input from the electronic medical record to flag critical medical conditions for anesthesiologists,” researcher and senior author Dr. Rodney Gabriel explained. “This research shows that NLP may be a useful tool to aid preoperative anesthesia providers in screening and evaluation of surgical patients.” For each of the 93 patients in the study, researchers collected all pertinent free-text notes from the EMR. The free-text notes were then processed by a Named Entity Recognition pipeline, which incorporated an NLP machine learning model developed by KAID Health. The model recognizes and labels spans of text that correspond to medical concepts. Medical concepts were then mapped to a list of medical conditions that were of interest for a preanesthesia evaluation. The most common conditions that the NLP pipeline captured that the anesthesiologist did not include cardiac arrhythmias, angina, anticoagulation, peripheral vascular disease, obstructive sleep apnea, and neuromuscular disease. “We are proud that leading academic institutions, such as UCSD, are partnering with KAID to ensure our NLP and AI models meet the demanding accuracy and usability standards required of the industry. KAID Health’s NLP technology played a vital role in this study in identifying pertinent preanesthesia history to optimize efficiency for anesthesiologists. Our model demonstrated that NLP holds the potential to reduce clinician workloads, improve profitability, and, most importantly, make surgery safer.” Kevin Agatstein, CEO of KAID Health The International Anesthesia Research Society published the study, “Identification of Preanesthetic History Elements by a Natural Language Processing Engine,” in its journal, Anesthesia & Analgesia, one of the leading anesthesiology journals in the world. About KAID Health KAID Health makes care delivery more efficient, effective, and profitable for providers and their payers and Accountable Care Organization partners. Its Whole Chart Analysis platform extracts all relevant data from electronic medical records, including structured data and text, using artificial intelligence and natural language processing. The solution identifies the patient care interventions needed for providers to achieve their clinical, financial, or operational objectives. In parallel, KAID Health extends to payers a comprehensive view of members’ health by combining claims and EMR data. Today, KAID Health’s technology is used by leading providers, health systems, academic medical centers, and payers to automate a variety of workflows, including coding accuracy, quality measurement, prior authorization support, and pre-operative assessment. The company was founded by a veteran team of healthcare information technology and population health innovators. It is based in Boston, MA.

Read More

HEALTH TECHNOLOGY

Nomi Health Acquires Everyone Health, Sano Surgery

Nomi Health | July 14, 2022

Everyone Health has agreements with self-funded employers and third-party administrators for pre-negotiated, all-inclusive prices that save employers up to 70% relative to commercial fee-for-service rates. The company delivers these savings via Sano Surgery’s direct contracting with more than 10,000 physicians and facilities — surgical hospitals, ambulatory surgery centers, endoscopy centers, radiology centers, labs and more — in 300 of the largest U.S. cities across 48 states, all now part of Nomi Health’s national provider network. “Nomi Health believes healthcare needs a rebuild, not a renovation. These companies share in our vision of extracting the complexity and cost from traditional healthcare, so buyers experience substantial savings and, most importantly, patients have greater access to more affordable care. In three short years, we expanded easy access to care to 15 million Americans, while significantly driving down cost of care to buyers. The immediate contributions of Everyone Health and Sano Surgery will accelerate this track record in the years ahead.” Mark Newman, founder and CEO of Nomi Health Founded by CEO Dutch Rojas 10 years ago, Sano Surgery has a network of nearly 6,000 medical facilities and 8,000 lab locations nationwide, ranging from radiology and orthopedics to women's health and oncology. This network enables Everyone Health to deliver higher quality medical treatments and services at lower prices. As a result, physicians benefit from predictable volumes and payments, while patients enjoy a more streamlined care and billing experience. “My goal is affordable and accessible healthcare for all. We’ve built a nationwide network of physicians and medical facilities that allows us to bring substantially lower pricing and more transparent transactions to the market, benefiting countless Americans,” said Rojas, founder and CEO of Sano Surgery and Everyone Health. “As the dual crisis of access and affordability grows on the heels of the pandemic, the time is right to increase our impact as part of Nomi Health.” The acquisitions enable buyers to turn to Nomi Health for a full suite of solutions — analytics, care delivery and a direct network — all underpinned by a modern claims infrastructure and payment rails. It also brings 12 full-time employees, including Rojas, to Nomi Health to accelerate the continued expansion of the company’s network of clinical partners, which is critical as Nomi Health takes its support and services into more communities nationwide. The acquisitions of Everyone Health and Sano Surgery come on the heels of Nomi’s $200 million acquisition of healthcare analytics leader Artemis Health in January. About Nomi Health Nomi Health is a nationwide direct healthcare system making it easier than ever for any buyer of healthcare to access the highest quality affordable care for their communities. The company’s direct care ecosystem encompasses a real-time operating and payment system — inclusive of analytics and payment rails — as well as an integrated care delivery infrastructure featuring essential care services, pharmacy and an open network. To date, Nomi Health has saved buyers of care an average of 30 percent compared to traditional healthcare costs, while enabling them to give their communities more access to lower cost, high quality care. From rural counties to some of the largest cities in America, Nomi Health has administered everyday healthcare services to more than 14 million Americans and counting in hundreds of communities nationwide. During COVID-19, this direct care model played a pivotal role in care access, public health and keeping economies open and operating. Based in Orem, Utah, Nomi Health employs more than 2,000 nationwide, working to lower healthcare expenses, widen care access and improve the patient experience. The company is led by an experienced, cross-functional leadership team with clinical, healthcare, technology and finance backgrounds. Nomi Health has so far invested more than $10 million dollars in improving the well-being of the communities it serves.

Read More

HEALTH TECHNOLOGY

Cardinal Health Announces Governance Enhancements and Shareholder Value Creation Initiatives

Cardinal Health | September 07, 2022

Cardinal Health announced initiatives aimed at positioning the Company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management L.P. In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the Company's Board of Directors. As part of Cardinal Health's ongoing commitment to Board refreshment and the initiatives announced today, the Governance and Sustainability Committee of the Board has recommended and the Board has approved the appointment of four new independent directors: Steven Barg, Michelle Brennan, Sujatha Chandrasekaran and Christine Mundkur. With these immediate appointments, Cardinal Health's Board will be made up of 15 Directors, 14 of whom are independent under the Company's director independence standards. Two existing Directors – Dean Scarborough and John Weiland – have announced their intentions to conclude their Board service at the end of their previously elected terms this fall and will not stand for re-election at Cardinal Health's 2022 Annual Meeting, resulting in a 13-member Board. Following the Annual Meeting, Cardinal Health's Board will consist of 54% women and 23% racially or ethnically diverse individuals. Cardinal Health's Board has also formed a new Board committee, the Business Review Committee, to support a comprehensive review of the Company's strategy, portfolio, capital-allocation framework, and operations with the goal of maximizing Cardinal Health's potential for the benefit of all stakeholders. The Business Review Committee will be chaired by Chief Executive Officer Jason Hollar; Mr. Barg and Akhil Johri will also serve on the Committee. The Committee, with the assistance of the Company's legal and financial advisors, will make recommendations to the full Board. The Company expects to conduct an investor day in the first half of calendar 2023 to share the Board's conclusions and to provide additional guidance. "We'd like to thank Dean and John for their service to the Board. We're grateful for their leadership and contributions and wish them both the very best. We're pleased to welcome Steven, Michelle, Sujatha and Christine to the Board and believe the Company and our many stakeholders will benefit from their mix of experience, skills and leadership. We are also pleased with Elliott's confidence in, and commitment to, the go-forward long-term potential of Cardinal Health. Our Board looks forward to receiving the recommendations of the Business Review Committee and updating the market in due course, as Jason and his leadership team chart a path to deliver upon our mission for our customers and employees and drive value creation for our shareholders." Gregory Kenny, Independent Chairman of the Board of Cardinal Health "Cardinal Health's leadership team is focused on creating value for all our stakeholders, and the newly initiated Business Review Committee, as well as the new expertise and experience being added to our Board, are critical steps in this process," said Mr. Hollar, Cardinal Health's Chief Executive Officer. "I look forward to working with the Board, including our four new directors, to optimize our strategy, structure, and operations as we position Cardinal Health for long-term success." Elliott Senior Portfolio Manager Marc Steinberg said, "Our discussions with Jason and the Board have been positive and productive, and we are pleased to have worked collaboratively to reach this agreement. Cardinal Health plays a mission-critical, market-leading role in the global healthcare system, and we have been encouraged by the Company's openness to taking actions necessary to ensuring that Cardinal Health realizes its full potential. We are confident that the initiatives announced today will drive meaningful shareholder value creation, and we look forward to continuing our collaboration with the Company." Michelle Brennan is Chair of Connect Healthcare Council for Pioneering Collective and serves on the Board of Coupa Software. Ms. Brennan spent more than 30 years at Johnson & Johnson, a leader in the field of medical devices, pharmaceutical, and consumer packaged goods, where she focused on driving growth, optimization and business transformation across diverse businesses and geographies. Most recently, Ms. Brennan served as the Global Value Creation Leader for Johnson & Johnson and as a member of the company's Medical Device Executive Leadership Team responsible for the division's value creation through cost management initiatives. Prior to that, Ms. Brennan held a number of positions at Johnson & Johnson, including Company Group Chair, Medical Devices (EMEA); President, Enterprise Standards & Productivity; Worldwide President, Ethicon Energy; as well as a variety of sales and marketing positions for other Johnson & Johnson divisions. Throughout her time at Johnson & Johnson, Ms. Brennan held significant board roles for the company, including Chairman of the Board for Medtech Europe Trading Association. She was previously a member of the UK's Office of Life Sciences Council and Chairman of the Council's Health Technology Partnership Committee. Ms. Brennan holds a B.S. from the University of Kansas. Sujatha Chandrasekaran, also known as Suja, is an advisor and independent consultant in the research and technology sectors. She currently serves on the Board of American Eagle Outfitters as well as private companies including Agendia, a molecular diagnostics company, and Blume Global, a digital supply chain platform company. Ms. Chandrasekaran has more than 25 years of experience in technology and leadership roles across the healthcare, consumer packaged goods and retail industries. Most recently, Ms. Chandrasekaran was Senior EVP & Chief Digital and Information Officer at CommonSpirit Health, one of the largest non-profit health systems in the US. Prior to that, she held a number of senior executive roles at several Fortune 500 multinational companies, including Global Chief Information Officer for Kimberly-Clark; SVP, Global Chief Technology and Data Officer for Walmart; as well as a number of C-level roles at The Timberland Company, PepsiCo and Nestlé SA. Ms. Chandrasekaran has a strong track record of delivering significant value to customers and organizations by leading global technology, supply chain and digital transformation initiatives. In 2022, Ms. Chandrasekaran was recognized by Modern Healthcare as one of the Top 25 Women Leaders in Healthcare. She was previously a Director of Symphony Technology Group and a Director of Barry Callebaut AG as well as a Member of Advisory Board at Atmio Inc. Ms. Chandrasekaran holds an Executive Development Education Certificate from London Business School; a Master of Business Systems/M.B.A. from Monash University in Melbourne, Australia; and a B.Eng. from the University of Madras, India. Christine Mundkur most recently served as Chief Executive Officer and Non-Voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. Ms. Mundkur currently serves on the Boards of Lupin Limited and MannKind Corporation. While at Impopharma, she led the transition of the company from a successful clinical research organization into a generic pharmaceutical inhalation development company. She also held leadership positions as President and Chief Executive Officer for North America for Sandoz, Inc. Earlier, she served as Chief Executive Officer of Barr Laboratories, Inc. Ms. Mundkur started her career at Barr as quality and regulatory counsel. In addition, she served as a strategic advisor to clients on generics, 505(b)2, biosimilars and NDA business strategies. Ms. Mundkur holds a J.D. from the St. Louis University School of Law and a B.S. from St. Louis University. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care.

Read More

HEALTH TECHNOLOGY

TELUS completes C$2.3 billion acquisition of LifeWorks setting a new course for employer-focused healthcare

TELUS Health | September 02, 2022

TELUS Corporation announced the completion of the previously disclosed acquisition by way of a plan of arrangement of LifeWorks Inc.a world leader in providing digital and in-person solutions that support the total wellbeing of individuals – mental, physical, financial and social, solidifying TELUS Health as one of the largest companies providing digital-first health and wellness services and solutions that empower individuals to live their healthiest lives. TELUS Health is now positioned to support corporate clients across more than 160 countries and covering more than 50 million lives and growing worldwide. “Today marks another exciting step in our TELUS Health journey, as we welcome the talented LifeWorks team, and the 36 million employees and family members of our business customers who they support, into our TELUS Health family,” said Darren Entwistle, President and CEO of TELUS. “As one of the largest health technology companies globally, our newly expanded TELUS Health organisation will provide employers across the globe with world-leading digital health and wellness solutions for their employees that are convenient, innovative and highly effective. Indeed, through the skill of our combined 10,000 team members and 30,000 independent health practitioners, and leveraging the combination of TELUS’ strong digital and data analytics capabilities with our client service excellence, we will dramatically improve remedial, preventative and mental health outcomes. In turn, this will support the well-being of over 50 million individuals and growing around the world. Importantly, LifeWorks’ domestic and global operations will be bolstered by our TELUS International team through their proven expertise in digital transformation and client service excellence. Moreover, we have an important opportunity to leverage our expansive TELUS and TELUS International footprint and client base spanning 32 countries, as well as the tremendous skill of our 70,000 international team members, to amplify the distribution reach, effectiveness and efficiency of our digital health services on a global basis. I look forward to the incredible opportunities before us to progress our goal of leveraging our globally leading technology, in combination with our social purpose-driven, client-centric culture and brand, to create better health experiences across the entire health and wellness ecosystem.” TELUS Health’s Chief Operating Officer, Michael Dingle, will oversee the transition and lead the integration of LifeWorks into the TELUS Health family. Michael’s deep industry expertise and proven track record of creating team, client and shareholder value will ensure the smooth transition of LifeWorks team members and clients. “TELUS Health and LifeWorks will work closely together to define the strategy and plan to thoughtfully integrate the teams with minimal disruption to internal and external stakeholders. We are excited to come together as one team as we begin this journey to raise the bar on employee health and wellness for organizations around the world.” Michael Dingle With the completion of the transaction, LifeWorks has become a wholly owned subsidiary of TELUS, and will continue to execute on its growth strategy, amplified by TELUS Health’s existing suite of advanced digital health technologies. LifeWorks brings world leading digital and in-person solutions that support the total wellbeing of individuals – mental, physical, financial and social. Also a trusted leader in mental health and wellbeing, LifeWorks delivers a personalized continuum of care that helps clients improve the lives of their people and by doing so, improves their business. As a part of the TELUS family, and by combining strengths with TELUS Health, together all clients globally have an opportunity to improve the wellbeing of their people, improve workforce engagement and productivity, which in turn improves the performance of their organizations. "We are excited to be joining the TELUS Health team to further advance our market-leading health and wellness offerings on a global scale to better serve our clients and their people," said Stephen Liptrap, President and CEO of LifeWorks. "Combining our international client relationships with TELUS' proven expertise in digital transformation and service excellence will unlock significant cross-selling opportunities and deliver value to all stakeholders." About TELUS Corporation TELUS is a dynamic, world-leading communications technology company with $17 billion in annual revenue and 17 million customer connections spanning wireless, data, IP, voice, television, entertainment, video, and security. Our social purpose is to leverage our global-leading technology and compassion to drive social change and enable remarkable human outcomes. Our longstanding commitment to putting our customers first fuels every aspect of our business, making us a distinct leader in customer service excellence and loyalty. The numerous, sustained accolades TELUS has earned over the years from independent, industry-leading network insight firms showcase the strength and speed of TELUS’ global-leading networks, reinforcing our commitment to provide Canadians with access to superior technology that connects us to the people, resources and information that make our lives better.

Read More

Spotlight

THE CANADIAN DIABETES RISK QUESTIONNAIRE (developed by the Public Health Agency of Canada) helps identify individuals that are at higher risk of having pre-diabetes or type 2 diabetes. The questionnaire is intended for adults aged 40 to 74 years. Pre-diabetes is a condition where a person‘s blood sugar levels are higher than normal, but not high enough to be diagnosed as diabetes. You can have pre-diabetes or undiagnosed type 2 diabetes without having any obvious warning signs or symptoms.

Resources